- Home
- EPAM vs ROIV Comparison
EPAM vs ROIV Comparison
Compare EPAM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | ROIV |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 14.1B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPAM | ROIV |
|---|---|---|
| Price | $210.85 | $21.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $217.50 | $21.19 |
| AVG Volume (30 Days) | 982.8K | ★ 6.5M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.55 | N/A |
| Revenue | ★ $5,297,859,000.00 | $20,329,000.00 |
| Revenue This Year | $17.39 | N/A |
| Revenue Next Year | $7.03 | $376.94 |
| P/E Ratio | $32.23 | ★ N/A |
| Revenue Growth | ★ 14.26 | N/A |
| 52 Week Low | $138.15 | $8.73 |
| 52 Week High | $269.00 | $22.05 |
Technical Indicators
Market Signals| Indicator | EPAM | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 83.84 | 63.54 |
| Support Level | $184.09 | $20.14 |
| Resistance Level | $187.17 | $21.48 |
| Average True Range (ATR) | 5.46 | 0.62 |
| MACD | 1.59 | -0.09 |
| Stochastic Oscillator | 90.24 | 72.01 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.